EVALUATION OF THE EFFICACY OF DEXMEDETOMIDINE IN COVID-19 DISEASE

dc.contributor.author	Mamadiev Khusanboy Ganijonovich
dc.date.accessioned	2025-12-31T15:37:01Z
dc.date.issued	2023-02-26
dc.description.abstract	The coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an ongoing global public health problem. Dexmedetomidine, sold under the trade name Precedex among others, is an anxiolytic, sedative and analgesic. Dexmedetomidine is notable for its ability to provide sedation without the risk of respiratory depression and can provide cooperative or semi-excitation.
dc.format	application/pdf
dc.identifier.uri	https://scholarexpress.net/index.php/wbph/article/view/2275
dc.identifier.uri	https://asianeducationindex.com/handle/123456789/49267
dc.language.iso	eng
dc.publisher	Scholar Express Journals
dc.relation	https://scholarexpress.net/index.php/wbph/article/view/2275/1959
dc.rights	https://creativecommons.org/licenses/by-nc-nd/4.0
dc.source	World Bulletin of Public Health; Vol. 19 (2023): WBPH; 287-288
dc.source	2749-3644
dc.subject	Coronavirus
dc.subject	drug
dc.subject	COVID-19
dc.subject	dexmedetomidine
dc.title	EVALUATION OF THE EFFICACY OF DEXMEDETOMIDINE IN COVID-19 DISEASE
dc.type	info:eu-repo/semantics/article
dc.type	info:eu-repo/semantics/publishedVersion
dc.type	Peer-reviewed Article

item.page.files

pagination.showing.labelpagination.showing.detail

item.page.filesection.name: ganijonovich_2023_evaluation_of_the_efficacy_of_dexmedetom.pdf
item.page.filesection.size: 126.21 KB
item.page.filesection.format: Adobe Portable Document Format